Our Competitive Advantage
Due to the lack of novel scaffolds being developed over the last few decades and limited investments into antibiotic R & D in recent years, the prevalence of resistant Gram-negative bacteria, especially in the hospital setting, has increased significantly. Even last-resort antibiotics such as colistin and polymyxin B are seeing increasing resistance by Gram-negative pathogens. Between 1999 and 2014, only 25 new antibiotics representing nine different antibiotic classes entered the global market. Furthermore, while 52% of new antibiotics were used to treat infections caused by resistant bacteria, none targeted Gram-negative bacteria, which are the cause of most untreatable infections. The combination of this dearth of new antibiotics against resistant Gram-negative pathogens, our unique peptide scaffold producing agents effective against bacterial pathogens that are resistant to antibiotics of last resort and the absence of eukaryotic cell toxicity and little, if any, chance of development of bacterial resistance places us in an excellent market situation. Indeed, we have no serious competition at the present time.